{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:36:12Z","timestamp":1707525372723},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,10]]},"DOI":"10.7759\/cureus.46790","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:45:58Z","timestamp":1696949158000},"source":"Crossref","is-referenced-by-count":0,"title":["Various Doses of Tanezumab in the Management of Chronic Low Back Pain (CLBP): A Pooled Analysis of 4,514 Patients"],"prefix":"10.7759","author":[{"given":"Sophia","family":"Tahir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oman","family":"Sadik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Ezenwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinenye","family":"Iguh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidhya","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naufin N","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica M","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rithika","family":"Sayabugari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Low back pain (chronic)","volume":"2010","author":"Chou R","year":"2010","unstructured":"Chou R. Low back pain (chronic). BMJ Clin Evid. 2010, 2010:1116.","journal-title":"BMJ Clin Evid"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4081\/hpr.2013.e27","article-title":"Quality of life in chronic disease patients","volume":"1","author":"Megari K","year":"2013","unstructured":"Megari K. Quality of life in chronic disease patients. Health Psychol Res. 2013, 1:e27. 10.4081\/hpr.2013.e27","journal-title":"Health Psychol Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3862946","article-title":"Low back pain and associated factors among primary school teachers in Mekele City, North Ethiopia: a cross-sectional study","volume":"2019","author":"Kebede A","year":"2019","unstructured":"Kebede A, Abebe SM, Woldie H, Yenit MK. Low back pain and associated factors among primary school teachers in Mekele City, North Ethiopia: a cross-sectional study. Occup Ther Int. 2019, 2019:3862946. 10.1155\/2019\/3862946","journal-title":"Occup Ther Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19052964","article-title":"A scoping review on the epidemiology of chronic low back pain among adults in sub-Saharan Africa","volume":"19","author":"Kahere M","year":"2022","unstructured":"Kahere M, Hlongwa M, Ginindza TG. A scoping review on the epidemiology of chronic low back pain among adults in sub-Saharan Africa. Int J Environ Res Public Health. 2022, 19:2964. 10.3390\/ijerph19052964","journal-title":"Int J Environ Res Public Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13013-017-0121-3","article-title":"Low back pain in older adults: risk factors, management options and future directions","volume":"12","author":"Wong AY","year":"2017","unstructured":"Wong AY, Karppinen J, Samartzis D. Low back pain in older adults: risk factors, management options and future directions. Scoliosis Spinal Disord. 2017, 12:14. 10.1186\/s13013-017-0121-3","journal-title":"Scoliosis Spinal Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2519\/jospt.2012.42.4.A1","article-title":"Low back pain","volume":"42","author":"Delitto A","year":"2012","unstructured":"Delitto A, George SZ, Van Dillen L, et al.. Low back pain. J Orthop Sports Phys Ther. 2012, 42:A1-57. 10.2519\/jospt.2012.42.4.A1","journal-title":"J Orthop Sports Phys Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5606\/tftrd.2021.8216","article-title":"Pharmacological and non-pharmacological treatment approaches to chronic lumbar back pain","volume":"67","author":"Ketenci A","year":"2021","unstructured":"Ketenci A, Zure M. Pharmacological and non-pharmacological treatment approaches to chronic lumbar back pain. Turk J Phys Med Rehabil. 2021, 67:1-10. 10.5606\/tftrd.2021.8216","journal-title":"Turk J Phys Med Rehabil"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2018.04.004","article-title":"Prescription medication use among community-based U.S. adults with chronic low back pain: a cross-sectional population based study","volume":"19","author":"Shmagel A","year":"2018","unstructured":"Shmagel A, Ngo L, Ensrud K, Foley R. Prescription medication use among community-based U.S. adults with chronic low back pain: a cross-sectional population based study. J Pain. 2018, 19:1104-12. 10.1016\/j.jpain.2018.04.004","journal-title":"J Pain"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g6380","article-title":"Opioids for low back pain","volume":"350","author":"Deyo RA","year":"2015","unstructured":"Deyo RA, Von Korff M, Duhrkoop D. Opioids for low back pain. BMJ. 2015, 350:g6380. 10.1136\/bmj.g6380","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/joacp.JOACP_389_15","article-title":"Tanezumab: therapy targeting nerve growth factor in pain pathogenesis","volume":"34","author":"Patel MK","year":"2018","unstructured":"Patel MK, Kaye AD, Urman RD. Tanezumab: therapy targeting nerve growth factor in pain pathogenesis. J Anaesthesiol Clin Pharmacol. 2018, 34:111-6. 10.4103\/joacp.JOACP_389_15","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001625","article-title":"Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety","volume":"160","author":"Schmelz M","year":"2019","unstructured":"Schmelz M, Mantyh P, Malfait AM, Farrar J, Yaksh T, Tive L, Viktrup L. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain. 2019, 160:2210-20. 10.1097\/j.pain.0000000000001625","journal-title":"Pain"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.12093","article-title":"Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management","volume":"124","author":"McKelvey L","year":"2013","unstructured":"McKelvey L, Shorten GD, O'Keeffe GW. Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. J Neurochem. 2013, 124:276-89. 10.1111\/jnc.12093","journal-title":"J Neurochem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1271873","article-title":"Tanezumab in the treatment of chronic musculoskeletal conditions","volume":"17","author":"Jayabalan P","year":"2017","unstructured":"Jayabalan P, Schnitzer TJ. Tanezumab in the treatment of chronic musculoskeletal conditions. Expert Opin Biol Ther. 2017, 17:245-54. 10.1080\/14712598.2017.1271873","journal-title":"Expert Opin Biol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.05.003","article-title":"Efficacy and safety of tanezumab in the treatment of chronic low back pain","volume":"152","author":"Katz N","year":"2011","unstructured":"Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, Brown MT. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain. 2011, 152:2248-58. 10.1016\/j.pain.2011.05.003","journal-title":"Pain"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15259","article-title":"Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain","volume":"88","author":"Shoji S","year":"2022","unstructured":"Shoji S, Suzuki A, Gaitonde P, Cai CH, Marshall S. Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain. Br J Clin Pharmacol. 2022, 88:3321-34. 10.1111\/bcp.15259","journal-title":"Br J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001928","article-title":"Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety","volume":"161","author":"Markman JD","year":"2020","unstructured":"Markman JD, Bolash RB, McAlindon TE, et al.. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. Pain. 2020, 161:2068-78. 10.1097\/j.pain.0000000000001928","journal-title":"Pain"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.03.006","article-title":"Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain","volume":"154","author":"Kivitz AJ","year":"2013","unstructured":"Kivitz AJ, Gimbel JS, Bramson C, et al.. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain. 2013, 154:1009-21. 10.1016\/j.pain.2013.03.006","journal-title":"Pain"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000354","article-title":"Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?","volume":"29","author":"Miller RE","year":"2017","unstructured":"Miller RE, Block JA, Malfait AM. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?. Curr Opin Rheumatol. 2017, 29:110-8. 10.1097\/BOR.0000000000000354","journal-title":"Curr Opin Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000986","article-title":"Relative efficacy and safety of tanezumab for osteoarthritis: a systematic review and meta-analysis of randomized-controlled trials","volume":"37","author":"Zhang B","year":"2021","unstructured":"Zhang B, Tian X, Qu Z, Liu J, Yang L. Relative efficacy and safety of tanezumab for osteoarthritis: a systematic review and meta-analysis of randomized-controlled trials. Clin J Pain. 2021, 37:914-24. 10.1097\/AJP.0000000000000986","journal-title":"Clin J Pain"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009, 6:e1000100. 10.1371\/journal.pmed.1000100","journal-title":"PLoS Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston M","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019, 10:ED000142. 10.1002\/14651858.ED000142","journal-title":"Cochrane Database Syst Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnw357","article-title":"Assessment of patient-reported outcome instruments to assess chronic low back pain","volume":"18","author":"Ramasamy A","year":"2017","unstructured":"Ramasamy A, Martin ML, Blum SI, et al.. Assessment of patient-reported outcome instruments to assess chronic low back pain. Pain Med. 2017, 18:1098-110. 10.1093\/pm\/pnw357","journal-title":"Pain Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3138\/ptc.2014-85","article-title":"A Roland Morris disability questionnaire target value to distinguish between functional and dysfunctional states in people with low back pain","volume":"68","author":"Stratford PW","year":"2016","unstructured":"Stratford PW, Riddle DL. A Roland Morris disability questionnaire target value to distinguish between functional and dysfunctional states in people with low back pain. Physiother Can. 2016, 68:29-35. 10.3138\/ptc.2014-85","journal-title":"Physiother Can"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2021-0040","article-title":"Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled\u00a0Japanese\u00a0Phase III\u00a0safety study","volume":"12","author":"Konno SI","year":"2022","unstructured":"Konno SI, Nikaido T, Markman JD, et al.. Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled\u00a0Japanese\u00a0Phase III\u00a0safety study. Pain Manag. 2022, 12:323-35. 10.2217\/pmt-2021-0040","journal-title":"Pain Manag"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.06.004","article-title":"Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain","volume":"155","author":"Gimbel JS","year":"2014","unstructured":"Gimbel JS, Kivitz AJ, Bramson C, et al.. Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain. Pain. 2014, 155:1793-801. 10.1016\/j.pain.2014.06.004","journal-title":"Pain"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-022-00424-7","article-title":"Clinical meaningfulness of response to tanezumab in patients with chronic low back pain: analysis from a 56-week, randomized, placebo- and tramadol-controlled, phase 3 trial","volume":"11","author":"Markman JD","year":"2022","unstructured":"Markman JD, Schnitzer TJ, Perrot S, et al.. Clinical meaningfulness of response to tanezumab in patients with chronic low back pain: analysis from a 56-week, randomized, placebo- and tramadol-controlled, phase 3 trial. Pain Ther. 2022, 11:1267-85. 10.1007\/s40122-022-00424-7","journal-title":"Pain Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000530","article-title":"Different dosage regimens of tanezumab for the treatment of chronic low back pain: a meta-analysis of randomized controlled trials","volume":"46","author":"Lian J","year":"2023","unstructured":"Lian J, Wang J, Li X, et al.. Different dosage regimens of tanezumab for the treatment of chronic low back pain: a meta-analysis of randomized controlled trials. Clin Neuropharmacol. 2023, 46:6-16. 10.1097\/WNF.0000000000000530","journal-title":"Clin Neuropharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S6775","article-title":"Nonsteroidal anti-inflammatory drugs in the treatment of low back pain","volume":"5","author":"Kuritzky L","year":"2012","unstructured":"Kuritzky L, Samraj GP. Nonsteroidal anti-inflammatory drugs in the treatment of low back pain. J Pain Res. 2012, 5:579-90. 10.2147\/JPR.S6775","journal-title":"J Pain Res"},{"key":"ref30","article-title":"Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population","volume":"57","author":"Kahan M","year":"2011","unstructured":"Kahan M, Mailis-Gagnon A, Wilson L, Srivastava A. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population. Can Fam Physician. 2011, 57:1257-66, e407-18.","journal-title":"Can Fam Physician"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00307","article-title":"Adverse effects of antidepressants for chronic pain: a systematic review and meta-analysis","volume":"8","author":"Riediger C","year":"2017","unstructured":"Riediger C, Schuster T, Barlinn K, Maier S, Weitz J, Siepmann T. Adverse effects of antidepressants for chronic pain: a systematic review and meta-analysis. Front Neurol. 2017, 8:307. 10.3389\/fneur.2017.00307","journal-title":"Front Neurol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004252","article-title":"Muscle relaxants for non-specific low back pain","volume":"2003","author":"van Tulder MW","year":"2003","unstructured":"van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003, 2003:CD004252. 10.1002\/14651858.CD004252","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/159098-various-doses-of-tanezumab-in-the-management-of-chronic-low-back-pain-clbp-a-pooled-analysis-of-4514-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:25Z","timestamp":1707509425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/159098-various-doses-of-tanezumab-in-the-management-of-chronic-low-back-pain-clbp-a-pooled-analysis-of-4514-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.46790","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,10]]}}}